Advertisement

Index by author

February 01, 1996; Volume 49,Issue 2

A

  1. al-Ani, B

    1. Proteinase-activated receptor-2 in rat aorta: structural requirements for agonist activity of receptor-activating peptides.
      M D Hollenberg, M Saifeddine and B al-Ani
      Molecular Pharmacology February 1996, 49 (2) 229-233;

  2. Arredondo, N F

    1. RS-17053 (N-[2-(2-cyclopropylmethoxyphenoxy)ethyl]-5-chloro-alpha, alpha-dimethyl-1H-indole-3-ethanamine hydrochloride), a selective alpha 1A-adrenoceptor antagonist, displays low affinity for functional alpha 1-adrenoceptors in human prostate: implications for adrenoceptor classification.
      A P Ford, N F Arredondo, D R Blue, D W Bonhaus, J Jasper, M S Kava, J Lesnick, J R Pfister, I A Shieh, R L Vimont, T J Williams, J E McNeal, T A Stamey and D E Clarke
      Molecular Pharmacology February 1996, 49 (2) 209-215;

B

  1. Bailly, C

    1. The 1'-substituent on the anilino ring of the antitumor drug amsacrine is a critical element for topoisomerase II inhibition and cytotoxicity.
      B Rene, P Fosse, T Khelifa, A Jacquemin-Sablon and C Bailly
      Molecular Pharmacology February 1996, 49 (2) 343-350;

  2. Bain, C

    1. Cloning of cDNAs encoding the human gamma-aminobutyric acid type A receptor alpha 6 subunit and characterization of the pharmacology of alpha 6-containing receptors.
      K L Hadingham, E M Garrett, K A Wafford, C Bain, R P Heavens, D J Sirinathsinghji and P J Whiting
      Molecular Pharmacology February 1996, 49 (2) 253-259;

  3. Bausch, S

    1. The conserved aspartate residue in the third putative transmembrane domain of the delta-opioid receptor is not the anionic counterpart for cationic opiate binding but is a constituent of the receptor binding site.
      K Befort, L Tabbara, S Bausch, C Chavkin, C Evans and B Kieffer
      Molecular Pharmacology February 1996, 49 (2) 216-223;

  4. Beavers, L S

    1. Expression cloning of a human brain neuropeptide Y Y2 receptor.
      D R Gehlert, L S Beavers, D Johnson, S L Gackenheimer, D A Schober and R A Gadski
      Molecular Pharmacology February 1996, 49 (2) 224-228;

  5. Beck, W T

    1. Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells.
      E G Schuetz, W T Beck and J D Schuetz
      Molecular Pharmacology February 1996, 49 (2) 311-318;

  6. Befort, K

    1. The conserved aspartate residue in the third putative transmembrane domain of the delta-opioid receptor is not the anionic counterpart for cationic opiate binding but is a constituent of the receptor binding site.
      K Befort, L Tabbara, S Bausch, C Chavkin, C Evans and B Kieffer
      Molecular Pharmacology February 1996, 49 (2) 216-223;

  7. Bindokas, V P

    1. Protective effect of transforming growth factor-beta 1 on beta-amyloid neurotoxicity in rat hippocampal neurons.
      J H Prehn, V P Bindokas, J Jordán, M F Galindo, G D Ghadge, R P Roos, L H Boise, C B Thompson, S Krajewski, J C Reed and R J Miller
      Molecular Pharmacology February 1996, 49 (2) 319-328;

  8. Blue, D R

    1. RS-17053 (N-[2-(2-cyclopropylmethoxyphenoxy)ethyl]-5-chloro-alpha, alpha-dimethyl-1H-indole-3-ethanamine hydrochloride), a selective alpha 1A-adrenoceptor antagonist, displays low affinity for functional alpha 1-adrenoceptors in human prostate: implications for adrenoceptor classification.
      A P Ford, N F Arredondo, D R Blue, D W Bonhaus, J Jasper, M S Kava, J Lesnick, J R Pfister, I A Shieh, R L Vimont, T J Williams, J E McNeal, T A Stamey and D E Clarke
      Molecular Pharmacology February 1996, 49 (2) 209-215;

  9. Boise, L H

    1. Protective effect of transforming growth factor-beta 1 on beta-amyloid neurotoxicity in rat hippocampal neurons.
      J H Prehn, V P Bindokas, J Jordán, M F Galindo, G D Ghadge, R P Roos, L H Boise, C B Thompson, S Krajewski, J C Reed and R J Miller
      Molecular Pharmacology February 1996, 49 (2) 319-328;

  10. Bonhaus, D W

    1. RS-17053 (N-[2-(2-cyclopropylmethoxyphenoxy)ethyl]-5-chloro-alpha, alpha-dimethyl-1H-indole-3-ethanamine hydrochloride), a selective alpha 1A-adrenoceptor antagonist, displays low affinity for functional alpha 1-adrenoceptors in human prostate: implications for adrenoceptor classification.
      A P Ford, N F Arredondo, D R Blue, D W Bonhaus, J Jasper, M S Kava, J Lesnick, J R Pfister, I A Shieh, R L Vimont, T J Williams, J E McNeal, T A Stamey and D E Clarke
      Molecular Pharmacology February 1996, 49 (2) 209-215;

  11. Bresnick, E

    1. Oct-1 transcription factor is a negative regulator of rat CYP1A1 expression via an octamer sequence in its negative regulatory element.
      K Sterling and E Bresnick
      Molecular Pharmacology February 1996, 49 (2) 329-337;

C

  1. Calmels, T P

    1. Genesis of discrete higher order DNA fragments in apoptotic human prostatic carcinoma cells.
      J M Rusnak, T P Calmels, D G Hoyt, Y Kondo, J C Yalowich and J S Lazo
      Molecular Pharmacology February 1996, 49 (2) 244-252;

  2. Carpenter, S P

    1. Expression, induction, and catalytic activity of the ethanol-inducible cytochrome P450 (CYP2E1) in human fetal liver and hepatocytes.
      S P Carpenter, J M Lasker and J L Raucy
      Molecular Pharmacology February 1996, 49 (2) 260-268;

  3. Chavkin, C

    1. The conserved aspartate residue in the third putative transmembrane domain of the delta-opioid receptor is not the anionic counterpart for cationic opiate binding but is a constituent of the receptor binding site.
      K Befort, L Tabbara, S Bausch, C Chavkin, C Evans and B Kieffer
      Molecular Pharmacology February 1996, 49 (2) 216-223;

  4. Clarke, D E

    1. RS-17053 (N-[2-(2-cyclopropylmethoxyphenoxy)ethyl]-5-chloro-alpha, alpha-dimethyl-1H-indole-3-ethanamine hydrochloride), a selective alpha 1A-adrenoceptor antagonist, displays low affinity for functional alpha 1-adrenoceptors in human prostate: implications for adrenoceptor classification.
      A P Ford, N F Arredondo, D R Blue, D W Bonhaus, J Jasper, M S Kava, J Lesnick, J R Pfister, I A Shieh, R L Vimont, T J Williams, J E McNeal, T A Stamey and D E Clarke
      Molecular Pharmacology February 1996, 49 (2) 209-215;

  5. Cook, V A

    1. Epitope mapping studies with human anti-cytochrome P450 3A antibodies.
      J S Leeder, A Gaedigk, X Lu and V A Cook
      Molecular Pharmacology February 1996, 49 (2) 234-243;

E

  1. Edwardson, J M

    1. Intracellular trafficking of the muscarinic acetylcholine receptor: importance of subtype and cell type.
      J A Koenig and J M Edwardson
      Molecular Pharmacology February 1996, 49 (2) 351-359;

  2. Evans, C

    1. The conserved aspartate residue in the third putative transmembrane domain of the delta-opioid receptor is not the anionic counterpart for cationic opiate binding but is a constituent of the receptor binding site.
      K Befort, L Tabbara, S Bausch, C Chavkin, C Evans and B Kieffer
      Molecular Pharmacology February 1996, 49 (2) 216-223;

F

  1. Felder, R A

    1. Dopamine D2L receptors stimulate Na+/K(+)-ATPase activity in murine LTK- cells.
      I Yamaguchi, S F Walk, P A Jose and R A Felder
      Molecular Pharmacology February 1996, 49 (2) 373-378;

  2. Ford, A P

    1. RS-17053 (N-[2-(2-cyclopropylmethoxyphenoxy)ethyl]-5-chloro-alpha, alpha-dimethyl-1H-indole-3-ethanamine hydrochloride), a selective alpha 1A-adrenoceptor antagonist, displays low affinity for functional alpha 1-adrenoceptors in human prostate: implications for adrenoceptor classification.
      A P Ford, N F Arredondo, D R Blue, D W Bonhaus, J Jasper, M S Kava, J Lesnick, J R Pfister, I A Shieh, R L Vimont, T J Williams, J E McNeal, T A Stamey and D E Clarke
      Molecular Pharmacology February 1996, 49 (2) 209-215;

  3. Fosse, P

    1. The 1'-substituent on the anilino ring of the antitumor drug amsacrine is a critical element for topoisomerase II inhibition and cytotoxicity.
      B Rene, P Fosse, T Khelifa, A Jacquemin-Sablon and C Bailly
      Molecular Pharmacology February 1996, 49 (2) 343-350;

G

  1. Gackenheimer, S L

    1. Expression cloning of a human brain neuropeptide Y Y2 receptor.
      D R Gehlert, L S Beavers, D Johnson, S L Gackenheimer, D A Schober and R A Gadski
      Molecular Pharmacology February 1996, 49 (2) 224-228;

  2. Gadski, R A

    1. Expression cloning of a human brain neuropeptide Y Y2 receptor.
      D R Gehlert, L S Beavers, D Johnson, S L Gackenheimer, D A Schober and R A Gadski
      Molecular Pharmacology February 1996, 49 (2) 224-228;

  3. Gaedigk, A

    1. Epitope mapping studies with human anti-cytochrome P450 3A antibodies.
      J S Leeder, A Gaedigk, X Lu and V A Cook
      Molecular Pharmacology February 1996, 49 (2) 234-243;

  4. Galindo, M F

    1. Protective effect of transforming growth factor-beta 1 on beta-amyloid neurotoxicity in rat hippocampal neurons.
      J H Prehn, V P Bindokas, J Jordán, M F Galindo, G D Ghadge, R P Roos, L H Boise, C B Thompson, S Krajewski, J C Reed and R J Miller
      Molecular Pharmacology February 1996, 49 (2) 319-328;

  5. Garrett, E M

    1. Cloning of cDNAs encoding the human gamma-aminobutyric acid type A receptor alpha 6 subunit and characterization of the pharmacology of alpha 6-containing receptors.
      K L Hadingham, E M Garrett, K A Wafford, C Bain, R P Heavens, D J Sirinathsinghji and P J Whiting
      Molecular Pharmacology February 1996, 49 (2) 253-259;

  6. Gehlert, D R

    1. Expression cloning of a human brain neuropeptide Y Y2 receptor.
      D R Gehlert, L S Beavers, D Johnson, S L Gackenheimer, D A Schober and R A Gadski
      Molecular Pharmacology February 1996, 49 (2) 224-228;

  7. Geoghegan, T E

    1. Regulation of CYP4A expression in rat by dehydroepiandrosterone and thyroid hormone.
      S J Webb, G H Xiao, T E Geoghegan and R A Prough
      Molecular Pharmacology February 1996, 49 (2) 276-287;

  8. Ghadge, G D

    1. Protective effect of transforming growth factor-beta 1 on beta-amyloid neurotoxicity in rat hippocampal neurons.
      J H Prehn, V P Bindokas, J Jordán, M F Galindo, G D Ghadge, R P Roos, L H Boise, C B Thompson, S Krajewski, J C Reed and R J Miller
      Molecular Pharmacology February 1996, 49 (2) 319-328;

H

  1. Hadingham, K L

    1. Cloning of cDNAs encoding the human gamma-aminobutyric acid type A receptor alpha 6 subunit and characterization of the pharmacology of alpha 6-containing receptors.
      K L Hadingham, E M Garrett, K A Wafford, C Bain, R P Heavens, D J Sirinathsinghji and P J Whiting
      Molecular Pharmacology February 1996, 49 (2) 253-259;

  2. Hanley, M R

    1. Stimulation of Ca(2+)-dependent membrane currents in Xenopus oocytes by microinjection of pyrimidine nucleotide-glucose conjugates.
      H Y Kim, D Thomas and M R Hanley
      Molecular Pharmacology February 1996, 49 (2) 360-364;

  3. Heavens, R P

    1. Cloning of cDNAs encoding the human gamma-aminobutyric acid type A receptor alpha 6 subunit and characterization of the pharmacology of alpha 6-containing receptors.
      K L Hadingham, E M Garrett, K A Wafford, C Bain, R P Heavens, D J Sirinathsinghji and P J Whiting
      Molecular Pharmacology February 1996, 49 (2) 253-259;

  4. Hefti, F

    1. Trophic effect of exogenous nerve growth factor on rat striatal cholinergic neurons: comparison between intraparenchymal and intraventricular administration.
      J L Venero, F Hefti and B Knusel
      Molecular Pharmacology February 1996, 49 (2) 303-310;

  5. Hermans, E

    1. Interaction of the COOH-terminal domain of the neurotensin receptor with a G protein does not control the phospholipase C activation but is involved in the agonist-induced internalization.
      E Hermans, J N Octave and J M Maloteaux
      Molecular Pharmacology February 1996, 49 (2) 365-372;

  6. Hollenberg, M D

    1. Proteinase-activated receptor-2 in rat aorta: structural requirements for agonist activity of receptor-activating peptides.
      M D Hollenberg, M Saifeddine and B al-Ani
      Molecular Pharmacology February 1996, 49 (2) 229-233;

  7. Holz, R W

    1. Effects of expression of a mouse brain L-type calcium channel alpha 1 subunit on secretion from bovine adrenal chromaffin cells.
      P F Wick, R E Westenbroek and R W Holz
      Molecular Pharmacology February 1996, 49 (2) 295-302;

  8. Hoyt, D G

    1. Genesis of discrete higher order DNA fragments in apoptotic human prostatic carcinoma cells.
      J M Rusnak, T P Calmels, D G Hoyt, Y Kondo, J C Yalowich and J S Lazo
      Molecular Pharmacology February 1996, 49 (2) 244-252;

J

  1. Jacquemin-Sablon, A

    1. The 1'-substituent on the anilino ring of the antitumor drug amsacrine is a critical element for topoisomerase II inhibition and cytotoxicity.
      B Rene, P Fosse, T Khelifa, A Jacquemin-Sablon and C Bailly
      Molecular Pharmacology February 1996, 49 (2) 343-350;

  2. Jasper, J

    1. RS-17053 (N-[2-(2-cyclopropylmethoxyphenoxy)ethyl]-5-chloro-alpha, alpha-dimethyl-1H-indole-3-ethanamine hydrochloride), a selective alpha 1A-adrenoceptor antagonist, displays low affinity for functional alpha 1-adrenoceptors in human prostate: implications for adrenoceptor classification.
      A P Ford, N F Arredondo, D R Blue, D W Bonhaus, J Jasper, M S Kava, J Lesnick, J R Pfister, I A Shieh, R L Vimont, T J Williams, J E McNeal, T A Stamey and D E Clarke
      Molecular Pharmacology February 1996, 49 (2) 209-215;

  3. Johnson, D

    1. Expression cloning of a human brain neuropeptide Y Y2 receptor.
      D R Gehlert, L S Beavers, D Johnson, S L Gackenheimer, D A Schober and R A Gadski
      Molecular Pharmacology February 1996, 49 (2) 224-228;

  4. Jordán, J

    1. Protective effect of transforming growth factor-beta 1 on beta-amyloid neurotoxicity in rat hippocampal neurons.
      J H Prehn, V P Bindokas, J Jordán, M F Galindo, G D Ghadge, R P Roos, L H Boise, C B Thompson, S Krajewski, J C Reed and R J Miller
      Molecular Pharmacology February 1996, 49 (2) 319-328;

  5. Jose, P A

    1. Dopamine D2L receptors stimulate Na+/K(+)-ATPase activity in murine LTK- cells.
      I Yamaguchi, S F Walk, P A Jose and R A Felder
      Molecular Pharmacology February 1996, 49 (2) 373-378;

K

  1. Kava, M S

    1. RS-17053 (N-[2-(2-cyclopropylmethoxyphenoxy)ethyl]-5-chloro-alpha, alpha-dimethyl-1H-indole-3-ethanamine hydrochloride), a selective alpha 1A-adrenoceptor antagonist, displays low affinity for functional alpha 1-adrenoceptors in human prostate: implications for adrenoceptor classification.
      A P Ford, N F Arredondo, D R Blue, D W Bonhaus, J Jasper, M S Kava, J Lesnick, J R Pfister, I A Shieh, R L Vimont, T J Williams, J E McNeal, T A Stamey and D E Clarke
      Molecular Pharmacology February 1996, 49 (2) 209-215;

  2. Khelifa, T

    1. The 1'-substituent on the anilino ring of the antitumor drug amsacrine is a critical element for topoisomerase II inhibition and cytotoxicity.
      B Rene, P Fosse, T Khelifa, A Jacquemin-Sablon and C Bailly
      Molecular Pharmacology February 1996, 49 (2) 343-350;

  3. Kieffer, B

    1. The conserved aspartate residue in the third putative transmembrane domain of the delta-opioid receptor is not the anionic counterpart for cationic opiate binding but is a constituent of the receptor binding site.
      K Befort, L Tabbara, S Bausch, C Chavkin, C Evans and B Kieffer
      Molecular Pharmacology February 1996, 49 (2) 216-223;

  4. Kim, H Y

    1. Stimulation of Ca(2+)-dependent membrane currents in Xenopus oocytes by microinjection of pyrimidine nucleotide-glucose conjugates.
      H Y Kim, D Thomas and M R Hanley
      Molecular Pharmacology February 1996, 49 (2) 360-364;

  5. Knusel, B

    1. Trophic effect of exogenous nerve growth factor on rat striatal cholinergic neurons: comparison between intraparenchymal and intraventricular administration.
      J L Venero, F Hefti and B Knusel
      Molecular Pharmacology February 1996, 49 (2) 303-310;

  6. Koenig, J A

    1. Intracellular trafficking of the muscarinic acetylcholine receptor: importance of subtype and cell type.
      J A Koenig and J M Edwardson
      Molecular Pharmacology February 1996, 49 (2) 351-359;

  7. Kondo, Y

    1. Genesis of discrete higher order DNA fragments in apoptotic human prostatic carcinoma cells.
      J M Rusnak, T P Calmels, D G Hoyt, Y Kondo, J C Yalowich and J S Lazo
      Molecular Pharmacology February 1996, 49 (2) 244-252;

  8. Krajewski, S

    1. Protective effect of transforming growth factor-beta 1 on beta-amyloid neurotoxicity in rat hippocampal neurons.
      J H Prehn, V P Bindokas, J Jordán, M F Galindo, G D Ghadge, R P Roos, L H Boise, C B Thompson, S Krajewski, J C Reed and R J Miller
      Molecular Pharmacology February 1996, 49 (2) 319-328;

L

  1. Lasker, J M

    1. Expression, induction, and catalytic activity of the ethanol-inducible cytochrome P450 (CYP2E1) in human fetal liver and hepatocytes.
      S P Carpenter, J M Lasker and J L Raucy
      Molecular Pharmacology February 1996, 49 (2) 260-268;

  2. Lazo, J S

    1. Genesis of discrete higher order DNA fragments in apoptotic human prostatic carcinoma cells.
      J M Rusnak, T P Calmels, D G Hoyt, Y Kondo, J C Yalowich and J S Lazo
      Molecular Pharmacology February 1996, 49 (2) 244-252;

  3. Leeder, J S

    1. Epitope mapping studies with human anti-cytochrome P450 3A antibodies.
      J S Leeder, A Gaedigk, X Lu and V A Cook
      Molecular Pharmacology February 1996, 49 (2) 234-243;

  4. Lemon, S C

    1. Stimulatory regulation of the large-conductance, calcium-activated potassium channel by G proteins in bovine adrenal chromaffin cells.
      K B Walsh, S P Wilson, K J Long and S C Lemon
      Molecular Pharmacology February 1996, 49 (2) 379-386;

  5. Lesnick, J

    1. RS-17053 (N-[2-(2-cyclopropylmethoxyphenoxy)ethyl]-5-chloro-alpha, alpha-dimethyl-1H-indole-3-ethanamine hydrochloride), a selective alpha 1A-adrenoceptor antagonist, displays low affinity for functional alpha 1-adrenoceptors in human prostate: implications for adrenoceptor classification.
      A P Ford, N F Arredondo, D R Blue, D W Bonhaus, J Jasper, M S Kava, J Lesnick, J R Pfister, I A Shieh, R L Vimont, T J Williams, J E McNeal, T A Stamey and D E Clarke
      Molecular Pharmacology February 1996, 49 (2) 209-215;

  6. Long, K J

    1. Stimulatory regulation of the large-conductance, calcium-activated potassium channel by G proteins in bovine adrenal chromaffin cells.
      K B Walsh, S P Wilson, K J Long and S C Lemon
      Molecular Pharmacology February 1996, 49 (2) 379-386;

  7. Lu, X

    1. Epitope mapping studies with human anti-cytochrome P450 3A antibodies.
      J S Leeder, A Gaedigk, X Lu and V A Cook
      Molecular Pharmacology February 1996, 49 (2) 234-243;

M

  1. Maloteaux, J M

    1. Interaction of the COOH-terminal domain of the neurotensin receptor with a G protein does not control the phospholipase C activation but is involved in the agonist-induced internalization.
      E Hermans, J N Octave and J M Maloteaux
      Molecular Pharmacology February 1996, 49 (2) 365-372;

  2. McNeal, J E

    1. RS-17053 (N-[2-(2-cyclopropylmethoxyphenoxy)ethyl]-5-chloro-alpha, alpha-dimethyl-1H-indole-3-ethanamine hydrochloride), a selective alpha 1A-adrenoceptor antagonist, displays low affinity for functional alpha 1-adrenoceptors in human prostate: implications for adrenoceptor classification.
      A P Ford, N F Arredondo, D R Blue, D W Bonhaus, J Jasper, M S Kava, J Lesnick, J R Pfister, I A Shieh, R L Vimont, T J Williams, J E McNeal, T A Stamey and D E Clarke
      Molecular Pharmacology February 1996, 49 (2) 209-215;

  3. Miller, R J

    1. Protective effect of transforming growth factor-beta 1 on beta-amyloid neurotoxicity in rat hippocampal neurons.
      J H Prehn, V P Bindokas, J Jordán, M F Galindo, G D Ghadge, R P Roos, L H Boise, C B Thompson, S Krajewski, J C Reed and R J Miller
      Molecular Pharmacology February 1996, 49 (2) 319-328;

O

  1. Octave, J N

    1. Interaction of the COOH-terminal domain of the neurotensin receptor with a G protein does not control the phospholipase C activation but is involved in the agonist-induced internalization.
      E Hermans, J N Octave and J M Maloteaux
      Molecular Pharmacology February 1996, 49 (2) 365-372;

P

  1. Pfister, J R

    1. RS-17053 (N-[2-(2-cyclopropylmethoxyphenoxy)ethyl]-5-chloro-alpha, alpha-dimethyl-1H-indole-3-ethanamine hydrochloride), a selective alpha 1A-adrenoceptor antagonist, displays low affinity for functional alpha 1-adrenoceptors in human prostate: implications for adrenoceptor classification.
      A P Ford, N F Arredondo, D R Blue, D W Bonhaus, J Jasper, M S Kava, J Lesnick, J R Pfister, I A Shieh, R L Vimont, T J Williams, J E McNeal, T A Stamey and D E Clarke
      Molecular Pharmacology February 1996, 49 (2) 209-215;

  2. Prehn, J H

    1. Protective effect of transforming growth factor-beta 1 on beta-amyloid neurotoxicity in rat hippocampal neurons.
      J H Prehn, V P Bindokas, J Jordán, M F Galindo, G D Ghadge, R P Roos, L H Boise, C B Thompson, S Krajewski, J C Reed and R J Miller
      Molecular Pharmacology February 1996, 49 (2) 319-328;

  3. Prough, R A

    1. Regulation of CYP4A expression in rat by dehydroepiandrosterone and thyroid hormone.
      S J Webb, G H Xiao, T E Geoghegan and R A Prough
      Molecular Pharmacology February 1996, 49 (2) 276-287;

R

  1. Raucy, J L

    1. Expression, induction, and catalytic activity of the ethanol-inducible cytochrome P450 (CYP2E1) in human fetal liver and hepatocytes.
      S P Carpenter, J M Lasker and J L Raucy
      Molecular Pharmacology February 1996, 49 (2) 260-268;

  2. Rayport, S

    1. Reserpine inhibits amphetamine action in ventral midbrain culture.
      D Sulzer, C St Remy and S Rayport
      Molecular Pharmacology February 1996, 49 (2) 338-342;

  3. Reed, J C

    1. Protective effect of transforming growth factor-beta 1 on beta-amyloid neurotoxicity in rat hippocampal neurons.
      J H Prehn, V P Bindokas, J Jordán, M F Galindo, G D Ghadge, R P Roos, L H Boise, C B Thompson, S Krajewski, J C Reed and R J Miller
      Molecular Pharmacology February 1996, 49 (2) 319-328;

  4. Rene, B

    1. The 1'-substituent on the anilino ring of the antitumor drug amsacrine is a critical element for topoisomerase II inhibition and cytotoxicity.
      B Rene, P Fosse, T Khelifa, A Jacquemin-Sablon and C Bailly
      Molecular Pharmacology February 1996, 49 (2) 343-350;

  5. Roos, R P

    1. Protective effect of transforming growth factor-beta 1 on beta-amyloid neurotoxicity in rat hippocampal neurons.
      J H Prehn, V P Bindokas, J Jordán, M F Galindo, G D Ghadge, R P Roos, L H Boise, C B Thompson, S Krajewski, J C Reed and R J Miller
      Molecular Pharmacology February 1996, 49 (2) 319-328;

  6. Rusnak, J M

    1. Genesis of discrete higher order DNA fragments in apoptotic human prostatic carcinoma cells.
      J M Rusnak, T P Calmels, D G Hoyt, Y Kondo, J C Yalowich and J S Lazo
      Molecular Pharmacology February 1996, 49 (2) 244-252;

S

  1. Saifeddine, M

    1. Proteinase-activated receptor-2 in rat aorta: structural requirements for agonist activity of receptor-activating peptides.
      M D Hollenberg, M Saifeddine and B al-Ani
      Molecular Pharmacology February 1996, 49 (2) 229-233;

  2. Schober, D A

    1. Expression cloning of a human brain neuropeptide Y Y2 receptor.
      D R Gehlert, L S Beavers, D Johnson, S L Gackenheimer, D A Schober and R A Gadski
      Molecular Pharmacology February 1996, 49 (2) 224-228;

  3. Schuetz, E G

    1. Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells.
      E G Schuetz, W T Beck and J D Schuetz
      Molecular Pharmacology February 1996, 49 (2) 311-318;

  4. Schuetz, J D

    1. Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells.
      E G Schuetz, W T Beck and J D Schuetz
      Molecular Pharmacology February 1996, 49 (2) 311-318;

  5. Shieh, I A

    1. RS-17053 (N-[2-(2-cyclopropylmethoxyphenoxy)ethyl]-5-chloro-alpha, alpha-dimethyl-1H-indole-3-ethanamine hydrochloride), a selective alpha 1A-adrenoceptor antagonist, displays low affinity for functional alpha 1-adrenoceptors in human prostate: implications for adrenoceptor classification.
      A P Ford, N F Arredondo, D R Blue, D W Bonhaus, J Jasper, M S Kava, J Lesnick, J R Pfister, I A Shieh, R L Vimont, T J Williams, J E McNeal, T A Stamey and D E Clarke
      Molecular Pharmacology February 1996, 49 (2) 209-215;

  6. Sinha, B K

    1. Interleukin-1 alpha-induced modulation of topoisomerase I activity and DNA damage: implications in the mechanisms of synergy with camptothecins in vitro and in vivo.
      Z Wang and B K Sinha
      Molecular Pharmacology February 1996, 49 (2) 269-275;

  7. Sirinathsinghji, D J

    1. Cloning of cDNAs encoding the human gamma-aminobutyric acid type A receptor alpha 6 subunit and characterization of the pharmacology of alpha 6-containing receptors.
      K L Hadingham, E M Garrett, K A Wafford, C Bain, R P Heavens, D J Sirinathsinghji and P J Whiting
      Molecular Pharmacology February 1996, 49 (2) 253-259;

  8. Smith, C D

    1. Microtubule effects of welwistatin, a cyanobacterial indolinone that circumvents multiple drug resistance.
      X Zhang and C D Smith
      Molecular Pharmacology February 1996, 49 (2) 288-294;

  9. Stamey, T A

    1. RS-17053 (N-[2-(2-cyclopropylmethoxyphenoxy)ethyl]-5-chloro-alpha, alpha-dimethyl-1H-indole-3-ethanamine hydrochloride), a selective alpha 1A-adrenoceptor antagonist, displays low affinity for functional alpha 1-adrenoceptors in human prostate: implications for adrenoceptor classification.
      A P Ford, N F Arredondo, D R Blue, D W Bonhaus, J Jasper, M S Kava, J Lesnick, J R Pfister, I A Shieh, R L Vimont, T J Williams, J E McNeal, T A Stamey and D E Clarke
      Molecular Pharmacology February 1996, 49 (2) 209-215;

  10. Sterling, K

    1. Oct-1 transcription factor is a negative regulator of rat CYP1A1 expression via an octamer sequence in its negative regulatory element.
      K Sterling and E Bresnick
      Molecular Pharmacology February 1996, 49 (2) 329-337;

  11. St Remy, C

    1. Reserpine inhibits amphetamine action in ventral midbrain culture.
      D Sulzer, C St Remy and S Rayport
      Molecular Pharmacology February 1996, 49 (2) 338-342;

  12. Sulzer, D

    1. Reserpine inhibits amphetamine action in ventral midbrain culture.
      D Sulzer, C St Remy and S Rayport
      Molecular Pharmacology February 1996, 49 (2) 338-342;

T

  1. Tabbara, L

    1. The conserved aspartate residue in the third putative transmembrane domain of the delta-opioid receptor is not the anionic counterpart for cationic opiate binding but is a constituent of the receptor binding site.
      K Befort, L Tabbara, S Bausch, C Chavkin, C Evans and B Kieffer
      Molecular Pharmacology February 1996, 49 (2) 216-223;

  2. Thomas, D

    1. Stimulation of Ca(2+)-dependent membrane currents in Xenopus oocytes by microinjection of pyrimidine nucleotide-glucose conjugates.
      H Y Kim, D Thomas and M R Hanley
      Molecular Pharmacology February 1996, 49 (2) 360-364;

  3. Thompson, C B

    1. Protective effect of transforming growth factor-beta 1 on beta-amyloid neurotoxicity in rat hippocampal neurons.
      J H Prehn, V P Bindokas, J Jordán, M F Galindo, G D Ghadge, R P Roos, L H Boise, C B Thompson, S Krajewski, J C Reed and R J Miller
      Molecular Pharmacology February 1996, 49 (2) 319-328;

V

  1. Venero, J L

    1. Trophic effect of exogenous nerve growth factor on rat striatal cholinergic neurons: comparison between intraparenchymal and intraventricular administration.
      J L Venero, F Hefti and B Knusel
      Molecular Pharmacology February 1996, 49 (2) 303-310;

  2. Vimont, R L

    1. RS-17053 (N-[2-(2-cyclopropylmethoxyphenoxy)ethyl]-5-chloro-alpha, alpha-dimethyl-1H-indole-3-ethanamine hydrochloride), a selective alpha 1A-adrenoceptor antagonist, displays low affinity for functional alpha 1-adrenoceptors in human prostate: implications for adrenoceptor classification.
      A P Ford, N F Arredondo, D R Blue, D W Bonhaus, J Jasper, M S Kava, J Lesnick, J R Pfister, I A Shieh, R L Vimont, T J Williams, J E McNeal, T A Stamey and D E Clarke
      Molecular Pharmacology February 1996, 49 (2) 209-215;

W

  1. Wafford, K A

    1. Cloning of cDNAs encoding the human gamma-aminobutyric acid type A receptor alpha 6 subunit and characterization of the pharmacology of alpha 6-containing receptors.
      K L Hadingham, E M Garrett, K A Wafford, C Bain, R P Heavens, D J Sirinathsinghji and P J Whiting
      Molecular Pharmacology February 1996, 49 (2) 253-259;

  2. Walk, S F

    1. Dopamine D2L receptors stimulate Na+/K(+)-ATPase activity in murine LTK- cells.
      I Yamaguchi, S F Walk, P A Jose and R A Felder
      Molecular Pharmacology February 1996, 49 (2) 373-378;

  3. Walsh, K B

    1. Stimulatory regulation of the large-conductance, calcium-activated potassium channel by G proteins in bovine adrenal chromaffin cells.
      K B Walsh, S P Wilson, K J Long and S C Lemon
      Molecular Pharmacology February 1996, 49 (2) 379-386;

  4. Wang, Z

    1. Interleukin-1 alpha-induced modulation of topoisomerase I activity and DNA damage: implications in the mechanisms of synergy with camptothecins in vitro and in vivo.
      Z Wang and B K Sinha
      Molecular Pharmacology February 1996, 49 (2) 269-275;

  5. Webb, S J

    1. Regulation of CYP4A expression in rat by dehydroepiandrosterone and thyroid hormone.
      S J Webb, G H Xiao, T E Geoghegan and R A Prough
      Molecular Pharmacology February 1996, 49 (2) 276-287;

  6. Westenbroek, R E

    1. Effects of expression of a mouse brain L-type calcium channel alpha 1 subunit on secretion from bovine adrenal chromaffin cells.
      P F Wick, R E Westenbroek and R W Holz
      Molecular Pharmacology February 1996, 49 (2) 295-302;

  7. Whiting, P J

    1. Cloning of cDNAs encoding the human gamma-aminobutyric acid type A receptor alpha 6 subunit and characterization of the pharmacology of alpha 6-containing receptors.
      K L Hadingham, E M Garrett, K A Wafford, C Bain, R P Heavens, D J Sirinathsinghji and P J Whiting
      Molecular Pharmacology February 1996, 49 (2) 253-259;

  8. Wick, P F

    1. Effects of expression of a mouse brain L-type calcium channel alpha 1 subunit on secretion from bovine adrenal chromaffin cells.
      P F Wick, R E Westenbroek and R W Holz
      Molecular Pharmacology February 1996, 49 (2) 295-302;

  9. Williams, T J

    1. RS-17053 (N-[2-(2-cyclopropylmethoxyphenoxy)ethyl]-5-chloro-alpha, alpha-dimethyl-1H-indole-3-ethanamine hydrochloride), a selective alpha 1A-adrenoceptor antagonist, displays low affinity for functional alpha 1-adrenoceptors in human prostate: implications for adrenoceptor classification.
      A P Ford, N F Arredondo, D R Blue, D W Bonhaus, J Jasper, M S Kava, J Lesnick, J R Pfister, I A Shieh, R L Vimont, T J Williams, J E McNeal, T A Stamey and D E Clarke
      Molecular Pharmacology February 1996, 49 (2) 209-215;

  10. Wilson, S P

    1. Stimulatory regulation of the large-conductance, calcium-activated potassium channel by G proteins in bovine adrenal chromaffin cells.
      K B Walsh, S P Wilson, K J Long and S C Lemon
      Molecular Pharmacology February 1996, 49 (2) 379-386;

X

  1. Xiao, G H

    1. Regulation of CYP4A expression in rat by dehydroepiandrosterone and thyroid hormone.
      S J Webb, G H Xiao, T E Geoghegan and R A Prough
      Molecular Pharmacology February 1996, 49 (2) 276-287;

Y

  1. Yalowich, J C

    1. Genesis of discrete higher order DNA fragments in apoptotic human prostatic carcinoma cells.
      J M Rusnak, T P Calmels, D G Hoyt, Y Kondo, J C Yalowich and J S Lazo
      Molecular Pharmacology February 1996, 49 (2) 244-252;

  2. Yamaguchi, I

    1. Dopamine D2L receptors stimulate Na+/K(+)-ATPase activity in murine LTK- cells.
      I Yamaguchi, S F Walk, P A Jose and R A Felder
      Molecular Pharmacology February 1996, 49 (2) 373-378;

Z

  1. Zhang, X

    1. Microtubule effects of welwistatin, a cyanobacterial indolinone that circumvents multiple drug resistance.
      X Zhang and C D Smith
      Molecular Pharmacology February 1996, 49 (2) 288-294;
Back to top

In this issue